# Lupin share price today (Lupin Ltd, NSE: LUPIN) > Lupin share price today: ₹1,971.90 at the NSE close on 18 November 2026, down 2.8% in a year. Lupin (NSE: LUPIN) is worth ₹90,188 crore, trades at a P/E of 17.3 and has closed between ₹1,928.90 and ₹2,496.30 over the past 52 weeks. > Lupin Ltd's P/E is near the low end of its own history, higher than only 4% of past readings, and its quarterly results are still getting worse. LUPIN · Pharma - Formulators · data as of 18 November 2026. Page: https://www.sectoralpha.in/stocks/lupin-ltd Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms ## Key numbers - Business trend: Mixed, from the last 12 quarters - Price: ₹1,971.90 (−2.8% in a year) - P/E: 17.3× (lower than 96% of the last 11 years) - Revenue (Sep 2026): ₹7,827 Cr (+11.1% on a year ago) - Profit (Sep 2026): ₹1,155 Cr (−22.2% on a year ago) - Operating margin: 26.1% (−7.1 points on a year ago) - ROCE: 30%, FY26 - ROIC: 24.3%, against a 12.0% cost of capital: +12.3 points The main question: yearly earnings per share moved +62.3% while the share price moved −2.8%. ## What is the Lupin share price today? Lupin Ltd's share price was ₹1,971.90 at the close on 18 November 2026. It has been falling for 7 weeks. That is 8.7% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,929 and ₹2,496, and at that close it sat 8% of the way up from that low. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 17 weeks running. Over the last 11 years the share price moved +14% while the NIFTY 500 moved +306%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Lupin this quarter? Three changes stood out: profit fell in the September 2026 quarter, revenue up on a year earlier for 13 quarters in a row (every quarter we can compare) and foreign funds (FIIs) raised their stake for 4 quarters in a row. 1. Profit fell in the September 2026 quarter Profit was ₹1,155 crore, -22.2% on a year earlier (₹1,485 crore), after 12 quarters of growth. Why: Profit fell because other operating income, money from export incentives, dropped sharply. Next results: check whether competition, research spending and input costs pull margins down in the second half. From the earnings call on 4 Nov 2026. 2. Revenue up on a year earlier for 13 quarters in a row (every quarter we can compare) In the September 2026 quarter revenue was ₹7,827 crore, +11.1% on a year earlier. Why: Revenue rose because sales in other developed markets, led by Australia and Canada, jumped. Next results: check whether India sales keep growing faster than the overall Indian pharma market, helped by breathing and heart drugs. From the earnings call on 4 Nov 2026. 3. Foreign funds (FIIs) raised their stake for 4 quarters in a row From 20.5% to 23.3% of the company by the September 2026 quarter. ## What are Lupin's latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Lupin reported revenue of ₹7,827 crore, up 11.1% from ₹7,048 crore a year earlier, and a profit of ₹1,155 crore, down 22.2% from ₹1,485 crore. ### Lupin results: July to September 2026 against a year earlier | Measure | July to September 2026 | July to September 2025 | Change | | --- | --- | --- | --- | | Revenue | ₹7,827 crore | ₹7,048 crore | +11.1% | | Profit | ₹1,155 crore | ₹1,485 crore | −22.2% | | Earnings per share | ₹25.26 | ₹32.36 | −21.9% | | Operating margin | 26.1% | 33.2% | −7.1 points | The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Lupin's management discussed these results on a call held on 4 November 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.) ## What is the Lupin share price history? Lupin closed at ₹1,971.90 on 18 November 2026, down 2.8% from ₹2,029.40 a year earlier (21 November 2025) and up 119.4% over five years. Its highest weekly close since February 2016 was ₹2,496.30 on 10 July 2026. ### Lupin share price: then and now | When | Close | Change to 18 Nov 2026 | | --- | --- | --- | | 1 week ago · 11 Nov 2026 | ₹2,023.40 | −2.5% | | 1 month ago · 19 Oct 2026 | ₹1,939.20 | +1.7% | | 6 months ago · 15 May 2026 | ₹2,276.20 | −13.4% | | 1 year ago · 21 Nov 2025 | ₹2,029.40 | −2.8% | | 3 years ago · 17 Nov 2023 | ₹1,196.30 | +64.8% | | 5 years ago · 18 Nov 2021 | ₹898.70 | +119.4% | | 10 years ago · 18 Nov 2016 | ₹1,417.75 | +39.1% | | Earliest weekly close in our records · 26 Feb 2016 | ₹1,726.75 | +14.2% | | Highest weekly close since February 2016, also the 52-week high · 10 Jul 2026 | ₹2,496.30 | −21.0% | | Lowest weekly close since February 2016 · 27 Mar 2020 | ₹548.10 | +259.8% | | 52-week low (weekly close) · 23 Oct 2026 | ₹1,928.90 | +2.2% | Weekly closing prices. Each change is the move from that price to the 18 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (568 weekly closes from 26 February 2016 to 18 November 2026.) ## What is the latest news on Lupin? 18 Nov 2026: Lupin closed at ₹1,971.90, down 2.5% on the week and up 1.7% on the month. 4 Nov 2026: Lupin held its results call for July to September 2026. Management guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged. ### Earlier - Results for July to September 2026: Revenue up 11.1% and profit down 22.2% on a year earlier. - 17 Jul 2026: ex-date for a dividend of ₹18 a share. ## What dividend does Lupin pay? Lupin paid ₹18 a share in regular dividends in the 12 months to 18 November 2026 (1 payment), a yield of 0.91% at the ₹1,971.90 close on 18 November 2026. The last was a dividend of ₹18 a share, ex-date 17 July 2026. ### Lupin dividends since 1 April 2021 | Ex-date | Dividend per share | Type | Record date | | --- | --- | --- | --- | | 17 Jul 2026 | ₹18 | Dividend | same day | | 25 Jul 2025 | ₹12 | Dividend | same day | | 16 Jul 2024 | ₹8 | Dividend | same day | | 14 Jul 2023 | ₹4 | Dividend | same day | | 14 Jul 2022 | ₹4 | Dividend | 15 Jul 2022 | | 27 Jul 2021 | ₹6.50 | Dividend | 28 Jul 2021 | Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 5 of 5 Of the last 5 financial years, years with an NSE dividend record Yes. Lupin Ltd paid out 15% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years. 2 of those years show a negative figure because profit itself was negative. (From the NSE corporate-actions record, read 18 November 2026.) ## What did Lupin management say on the latest results call? On the call for July to September 2026, held on 4 November 2026, Lupin's management guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged. > “give us the confidence that we should be able to evolve our developed-market business into a more durable, more sustainable portfolio going forward, as opposed to the one-off exclusives.” > Vinita, closing remarks, on the call for July to September 2026 ### What management guided - H2 organic growth around 20% ex-US; India formulations 1.2-1.3 times IPM. - Full-year R&D around 8% focused on complex and specialty platforms. - Full-year ETR 27-28% with H1 at 28.5%. - More than 15 US submissions in FY27; more than 60 launches next 3 years including 25 injectable, respiratory, 5 biosimilars and 2-3 505(b)(2)s. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/187/Conference Call/CC-Nov26.pdf). (From the call for July to September 2026, 4 November 2026.) ## What to watch in Lupin's next results? When Lupin reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Tolvaptan entrant tally and pricing versus share erosion into next print with flagged further competition. Management raised each of these on the latest results call. - Tolvaptan entrant tally and pricing versus share erosion into next print with flagged further competition. - Apixaban final approval progress toward guided launch window with planned-channel traction and share build check. - India growth multiple versus IPM with respiratory pickup, cardiac bounce and chronic mix check. ## Which stock lists is Lupin on? Lupin is on 3 of our India lists: 52 week high & low, Small & mid cap stocks and Pharma stocks. - [52 week high & low 52-week position: Near 52-week low](https://www.sectoralpha.in/52-week-high-stocks-india) - [Small & mid cap stocks Size rank in India: 125](https://www.sectoralpha.in/small-cap-stocks-india) - [Pharma stocks Market value: ₹89,172 crore](https://www.sectoralpha.in/sectors/pharma-stocks-india) ## Is Lupin profitable? Lupin Ltd earned ₹1,155 Cr of net profit in the Sep 2026 quarter, −22.2% on the same quarter a year earlier. Full-year FY26 profit was ₹5,355 Cr. Over 10 years profit has grown 9.0% a year on average. The Sep 2026 quarter's profit is 14.8% of that quarter's revenue. The same quarter a year earlier earned ₹1,485 Cr. For the full year, FY26 profit was ₹5,355 Cr (+62.0% on the year before). Why profit moved: revenue changed +11.1% on a year earlier and the margin moved −7.1 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed +29.8% and revenue +24.9%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Lupin make, and is it growing? Lupin Ltd reported ₹7,827 Cr of revenue in the Sep 2026 quarter, +11.1% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹27,958 Cr. The last four reported quarters add to ₹30,747 Cr. FY26 revenue was ₹27,958 Cr, +23.1% on the year before. Recent pace: the last four quarters grew +24.9% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +24.2%, against +19.8% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +20.1%, against +40.3% a year (rolling over). ## How much of every ₹100 of sales does Lupin keep? Lupin Ltd's operating margin was 26.1% in the Sep 2026 quarter, 7.1 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 1.3% and 29.2%. The latest quarter is within that range. Why this happened. Emerging-markets sales rose on Brazil, South Africa and the Philippines, while Europe benefited from VISUfarma consolidation. This reduces dependence on a single US exclusivity product, but these businesses must keep converting launches into recurring revenue. Why the margin moved: operating margin changed −7.1 percentage points on the year while gross margin changed +0.2 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Lupin's profit turning into cash? Over the last 3 years, 132% of Lupin Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹7,334 Cr of operating cash against ₹5,355 Cr of profit. After ₹2,055 Cr of spending on assets, ₹5,280 Cr was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 132% of profit came in as cash: the cash cycle got 68 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Lupin's cash go? Lupin Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 181 days in FY26, down from 249 days in FY21. It spent ₹4,666 Cr on assets over the last 3 years. Customers take 86 days to pay, and stock sits for 303 days on average. At FY26 sales of ₹27,958 Cr, each day of that cycle ties up about ₹76.6 Cr, so roughly ₹13,864 Cr is tied up in the business at any time. FY26: customers took 86 days to pay and stock sat for 303 days, about 10.0 months of sales sitting as stock, for a full cycle of 181 days, shorter than FY21's 249. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 303 days. Customers pay about 86 days after that. Suppliers are paid at 208 days. Together that makes the 181-day cycle. Spending on assets: ₹4,666 Cr over the last 3 years, against ₹3,742 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹1,016 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Lupin's P/E ratio, and how does it compare with its own history? Lupin Ltd's P/E is 17.3×, near the low end of its own history: it has been lower only 4% of the time. Its usual P/E (the middle reading) is 29.2×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹113.88. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Why the multiple is where it is: over the past year earnings per share moved +62.3% while the price moved −2.8%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved +17.0% a year; about +27.6% a year came from earnings growth and about −10.6 percentage points from the multiple (the market paying less); over 10 years the price moved +3.4% a year; about +7.0% a year came from earnings growth and about −3.6 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## What growth does the Lupin share price assume? Worked out from its price on 24 August 2026, Lupin Ltd's share price assumed profit growth of about 9.1% a year. Over the past 10 years its profit actually grew 9.0% a year. Today its P/E is 17.3×, lower than 96% of its own last 11 years. This is a one-day reading, taken on 24 August 2026. Every other number on this page, the multiple included, uses the latest price as of 18 November 2026. A higher price assumes more growth and a lower price less, so it changes whenever the price changes, and this page does not update it between measurements. ## Is the Lupin business getting better or worse? Lupin Ltd's business is giving mixed signals. Growth is slowing from a very fast pace: profit growth has eased from +334.8% at its peak to +20.1%, but the business is still expanding, with ROCE steady at 30.0% (four quarters to Sep 2026). This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## What is the Lupin story, and has it been checked? Lupin Ltd's story is not scored yet against the checks our research set on 22 August 2026. Where it sits in its own cycle: mid expansion with peak margin risk. Still open: A sustained operating margin below management's FY27 framework after Tolvaptan competition, without a measurable launch offset from Pegfilgrastim or other complex products, would break the thesis. Our read, 22 August 2026. From the numbers. The operating cycle remains in expansion rather than… From the price. Price stage 4, week 7, below its 200-day line, relative strength falling. Where they disagree. The operating cycle remains in expansion rather than a confirmed trough. What is not proven yet. A sustained operating margin below management's FY27 framework after Tolvaptan competition, without a measurable launch offset from Pegfilgrastim or other complex products, would break the thesis. The test written in advance. US competition and product erosion. Measured by: US competition and product erosion by the next result. The test written in advance. What the company does. The latest quarter extended revenue growth while reported profit grew more slowly because tax rose and operating margin eased from the preceding peak. What the surface reading misses. The surface reading is: A 30% operating margin reads as sustained high profitability. The research reads it further: The normalized analysis places current operating margin above the through-cycle estimate, while management cites competition, development spending and cost inflation as prospective pressures. What the surface reading misses. Lever 1 · Operating leverage: building. Brazil-led emerging markets and other developed markets broaden growth beyond the US portfolio. What proves it keeps working: International growth diversification. It stops working if Brazil's metabolic launches fail to sustain growth or VISUfarma does not convert its new distribution footprint into sales. Lever 2 · Value-added mix: building. Respiratory, injectables, biosimilars and 505(b)(2) programs are intended to replace fading US exclusivity economics. What proves it keeps working: Complex-product pipeline. It stops working if Regulatory remediation delays approvals or launch dates move beyond the period in which Tolvaptan revenue is falling. Lever 3 · Management change: building. Chronic mix, diabetes launches and prescription growth provide a domestic counterweight to US volatility. What proves it keeps working: India chronic and metabolic franchise. It stops working if Core prescription growth falls below the market after new-product launches and the chronic mix ceases rising. Sources: our stock research file (22 August 2026) · quarterly results through Sep 2026 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes. ## Did Lupin management deliver what it promised? What Lupin Ltd's management promised, against what actually happened: 4 promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met. US FY28 Growth Outlook Softened · 4 November 2026. In Aug 2026, management said the U.S. business would return to a growth trajectory from FY28. In Nov 2026, management instead said it hoped only to maintain at least USD 1 billion plus and acknowledged it might not match FY27, moving the next explicit growth expectation to FY29; the additional competition cited in the latest call was not reconciled with the earlier growth forecast. FY27 ETR Guidance Changed Without Reconciliation · 4 November 2026. In May 2026, management guided FY27 ETR to 25%-26%, while the Nov 2026 call stated 27%-28%, a two-point increase in the expected tax burden that affects earnings conversion. The latest call did not reconcile this higher range with the earlier guidance; the same 27%-28% range had appeared in Aug 2026, so this is an unreconciled change carried forward rather than a new Nov 2026 revision. FY27 Tax Rate Guidance Raised · 7 August 2026. In May 2026, management guided to a 25%-26% FY27 effective tax rate and explicitly cited the phase-out of incentives. In August 2026, management raised the range to 27%-28% without explaining what changed, creating a material adverse revision to earnings expectations. Dulera Launch Timing Becomes Conditional · 7 August 2026. In May 2026, management expected Dulera to be in the market in FY28. In August 2026, FY28 became only a possibility and FY29 was introduced as the fallback, with no explanation for the timeline slippage. Every quote above is taken word for word from the company’s own earnings calls. ## What is Lupin management's track record? Strong quantitative delivery through the US generics cycle, but one material said-vs-delivered credibility flag. 0% Promoter shares pledged (Checked 21 July 2026.) ## How much does Lupin earn on its capital? Lupin Ltd earned a ROCE of 30% in FY26. That is up from a low of −7% in FY22. Its return on capital used (ROIC) is 12.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 19.2% net margin and 0.73× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 19.2% net margin × 0.73× asset turnover × 1.70× leverage (assets divided by equity) ≈ 23.8% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 24.3% − 12.0% = +12.3 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. A gap this wide means each rupee put back into the business creates more than a rupee of value. The 24.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 26.1%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Lupin have too much debt? Lupin Ltd has total debt of ₹6,180 Cr against shareholder equity of ₹24,050 Cr as of Sep 2026, so its debt is 0.26× its equity, which is very little. Year by year, that ratio went from 0.34 in FY22 to 0.29 in FY26. So the returns on this page come from the business, not from borrowed money. Why this happened. The multi-year cash record supports reinvestment, though payable-led cash-cycle improvement means cash quality should be monitored alongside reported profit. ## What is the Lupin shareholding pattern? Foreign institutions raised their stake in Lupin Ltd by 1.8 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 23.3% of the company. Domestic institutions moved −1.3 points over the same period, to 23.8%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Why this happened. India sales grew faster than the India pharmaceutical market in the latest quarter, led by diabetes and a higher chronic mix. The chronic-therapy annuity premium applies if launch-led growth remains durable rather than being confined to an initial product burst. Over the last two years: Foreign institutions: +1.8 points over 8 quarters, to 23.3%; Domestic institutions: −1.3 points over 8 quarters, to 23.8%; Promoters: −0.1 points over 8 quarters, to 46.8%. Why the owners changed: foreign institutions drove it (+1.8 points), with the other side taken by domestic institutions (−1.3 points). They raised their stake step by step. ## How far is Lupin from balance-sheet trouble? For Lupin Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Lupin rank in its industry? 57.2 out of 100, rank 15 of 44 in Pharma - Formulators, with 90% of the evidence available. Lupin Ltd scores 57.2 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 15. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 20.8 + 20.2 + 14.7 + 1.5 = 57.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Lupin compared with? Lupin ranks 15 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 57.2 out of 100. 1. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · losing its lead · Most evidence points up · 78% evidence 75.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.5/35 · Revenue 24.2% · Profit 60.3% · Operating margin change 3 points · 100% evidence Capital efficiency 18.0/25 · ROCE 18.8% (year to Mar 2026) · Operating margin 22.8% · 100% evidence Valuation 15.4/20 · P/E 23.8× · PEG 0.92 · 65% evidence Relative strength 11.9/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 31.3% · 1 year 53.6% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30.5 + 18 + 15.4 + 11.9 = 75.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · leader · Most evidence points up · 75% evidence 72.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 21.1% · Profit 33.3% · Operating margin change 0 points · 95% evidence Capital efficiency 18.0/25 · ROCE 24% (year to Mar 2026) · Operating margin 20.9% · 76% evidence Valuation 10.0/20 · P/E 40.5× · PEG n/a · 15% evidence Relative strength 18.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 17.5% · Strength vs NIFTY 500 (same reading) 33.7% · 1 year 72.4% · 100% evidence · 10 of 12 weeks ahead Exact sum: 26.1 + 18 + 10 + 18.7 = 72.8 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 75% evidence 68.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 32.5/35 · Revenue 47.6% · Profit 95.9% · Operating margin change 4 points · 100% evidence Capital efficiency 17.0/25 · ROCE 24.1% (year to Mar 2026) · Operating margin 27.6% · 100% evidence Valuation 6.5/20 · P/E 45.5× · PEG n/a · 50% evidence Relative strength 12.3/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 68.2% · 1 year 345.7% · 25% evidence · 9 of 9 weeks ahead Exact sum: 32.5 + 17 + 6.5 + 12.3 = 68.3 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · losing its lead · Most evidence points up · 87% evidence 67.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 46.3% · Profit 90.1% · Operating margin change 2 points · 100% evidence Capital efficiency 18.8/25 · ROCE 28.4% (year to Mar 2026) · Operating margin 25% · 100% evidence Valuation 8.1/20 · P/E 84.3× · PEG 2.11 · 65% evidence Relative strength 16.5/20 · Strength vs its industry (price vs its 52-week average, weekly) 28.5% · Strength vs NIFTY 500 (same reading) 42.3% · 1 year 144.6% · 70% evidence · 10 of 12 weeks ahead Exact sum: 24 + 18.8 + 8.1 + 16.5 = 67.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 5. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · losing its lead · Most evidence points up · 65% evidence 66.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.6/25 · ROCE 24.9% (year to Mar 2026) · Operating margin 23.4% · 100% evidence Valuation 10.1/20 · P/E 25.6× · PEG n/a · 50% evidence Relative strength 12.7/20 · Strength vs its industry (price vs its 52-week average, weekly) 13.6% · Strength vs NIFTY 500 (same reading) 27.2% · 1 year 97.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 21.8 + 21.6 + 10.1 + 12.7 = 66.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · quiet · Most evidence points up · 100% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.1/25 · ROCE 34.5% (year to Mar 2026) · Operating margin 30.6% · 100% evidence Valuation 9.2/20 · P/E 32.4× · PEG 1.91 · 100% evidence Relative strength 5.1/20 · Strength vs its industry (price vs its 52-week average, weekly) -10.2% · Strength vs NIFTY 500 (same reading) 2.4% · 1 year 31.7% · 100% evidence · 8 of 12 weeks ahead Exact sum: 30.3 + 21.1 + 9.2 + 5.1 = 65.7 · What this means: Earnings are strong; relative strength in its sector is -10.2% and the one-year return is 31.7%. 7. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Most evidence points up · 100% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.3/35 · Revenue 13.5% · Profit 27.5% · Operating margin change 2 points · 100% evidence Capital efficiency 15.8/25 · ROCE 13.5% (year to Mar 2026) · Operating margin 27% · 100% evidence Valuation 10.4/20 · P/E 48.3× · PEG 2.64 · 100% evidence Relative strength 12.8/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.4% · Strength vs NIFTY 500 (same reading) 10.8% · 1 year 17.1% · 100% evidence · 4 of 12 weeks ahead Exact sum: 26.3 + 15.8 + 10.4 + 12.8 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 65.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.2/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.5/25 · ROCE 16.9% (year to Mar 2026) · Operating margin 25.9% · 76% evidence Valuation 6.5/20 · P/E 44.8× · PEG n/a · 50% evidence Relative strength 14.1/20 · Strength vs its industry (price vs its 52-week average, weekly) 55.9% · Strength vs NIFTY 500 (same reading) 69.5% · 1 year 325.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 30.2 + 14.5 + 6.5 + 14.1 = 65.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · leader · Evidence leans up · 85% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 19.7% · Profit 32.7% · Operating margin change 5 points · 100% evidence Capital efficiency 12.1/25 · ROCE 12.6% (year to Mar 2026) · Operating margin 21.6% · 100% evidence Valuation 14.5/20 · P/E 24.3× · PEG 1.28 · 100% evidence Relative strength 11.6/20 · Strength vs its industry (price vs its 52-week average, weekly) n/a · Strength vs NIFTY 500 (same reading) 24.7% · 1 year 15.9% · 25% evidence · 9 of 12 weeks ahead Exact sum: 25.8 + 12.1 + 14.5 + 11.6 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · leader · Evidence leans up · 82% evidence 62.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.5/35 · Revenue 12% · Profit 73.8% · Operating margin change 2 points · 95% evidence Capital efficiency 15.7/25 · ROCE 17% (year to Mar 2026) · Operating margin 23.1% · 76% evidence Valuation 11.7/20 · P/E 33.5× · PEG n/a · 50% evidence Relative strength 10.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -3.6% · Strength vs NIFTY 500 (same reading) 9.9% · 1 year 28.4% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.5 + 15.7 + 11.7 + 10.5 = 62.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · losing its lead · Evidence leans up · 70% evidence 61.2 out of 100 Growth Capital Valuation Relative 12. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · turning · Evidence leans up · 75% evidence 59.2 out of 100 Growth Capital Valuation Relative 13. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans up · 100% evidence 58.9 out of 100 Growth Capital Valuation Relative 14. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · breaking out · Evidence leans up · 73% evidence 58.3 out of 100 Growth Capital Valuation Relative 15. Lupin Ltd this page LUPIN · quiet · Evidence leans up · 90% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 24.2% · Profit 20.1% · Operating margin change -7 points · 100% evidence Capital efficiency 20.2/25 · ROCE 29.9% (year to Mar 2026) · Operating margin 26.1% · 100% evidence Valuation 14.7/20 · P/E 17.3× · PEG n/a · 50% evidence Relative strength 1.5/20 · Strength vs its industry (price vs its 52-week average, weekly) -25.2% · Strength vs NIFTY 500 (same reading) -13.6% · 1 year -2.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 20.8 + 20.2 + 14.7 + 1.5 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 75% evidence 56.8 out of 100 Growth Capital Valuation Relative 17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.0 out of 100 Growth Capital Valuation Relative 18. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · turning · Evidence leans up · 82% evidence 55.8 out of 100 Growth Capital Valuation Relative 19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · quiet · Evidence leans up · 90% evidence 55.2 out of 100 Growth Capital Valuation Relative 20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 83% evidence 54.7 out of 100 Growth Capital Valuation Relative 21. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Evidence leans up · 63% evidence 54.3 out of 100 Growth Capital Valuation Relative 22. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · breaking out · Evidence leans up · 90% evidence 54.1 out of 100 Growth Capital Valuation Relative 23. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · losing its lead · Evidence leans up · 75% evidence 53.3 out of 100 Growth Capital Valuation Relative 24. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 82% evidence 52.3 out of 100 Growth Capital Valuation Relative 25. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · breaking out · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative 26. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Evidence leans up · 90% evidence 50.6 out of 100 Growth Capital Valuation Relative 27. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 68% evidence 49.1 out of 100 Growth Capital Valuation Relative 28. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 82% evidence 48.3 out of 100 Growth Capital Valuation Relative 29. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 45.8 out of 100 Growth Capital Valuation Relative 30. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.8 out of 100 Growth Capital Valuation Relative 31. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 74% evidence 42.8 out of 100 Growth Capital Valuation Relative 32. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · basing · Evidence leans down · 90% evidence 42.7 out of 100 Growth Capital Valuation Relative 33. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 90% evidence 41.5 out of 100 Growth Capital Valuation Relative 34. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.8 out of 100 Growth Capital Valuation Relative 35. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 90% evidence 38.9 out of 100 Growth Capital Valuation Relative 36. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · turning · Too little evidence to rank firmly · 52% evidence 37.8 out of 100 Growth Capital Valuation Relative 37. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 67% evidence 34.4 out of 100 Growth Capital Valuation Relative 38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · quiet · Most evidence points down · 100% evidence 34.2 out of 100 Growth Capital Valuation Relative 39. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Most evidence points down · 90% evidence 31.9 out of 100 Growth Capital Valuation Relative 40. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · breaking out · Most evidence points down · 100% evidence 30.4 out of 100 Growth Capital Valuation Relative 41. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · quiet · Most evidence points down · 100% evidence 27.9 out of 100 Growth Capital Valuation Relative 42. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · basing · Most evidence points down · 100% evidence 22.7 out of 100 Growth Capital Valuation Relative 43. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.4 out of 100 Growth Capital Valuation Relative 44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · quiet · Too little evidence to rank firmly · 36% evidence 38.3 out of 100 Growth Capital Valuation Relative Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. In this ranking every company's P/E uses its own latest official close and its last four filed quarters, the same rule as the top of this page. ROCE here is each company's last full year, as labelled, so it can differ from the four-quarter ROCE above. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Lupin in size? Lupin is the 8th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (at the 18 November 2026 close). Just above it: Cipla, Mankind Pharma and Aurobindo Pharma. Just below it: Glenmark Pharmaceuticals, Alkem Laboratories and Biocon. ### Pharma - Formulators companies close in size 1. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) ₹1,14,478 crore 2. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) ₹1,08,424 crore 3. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) ₹1,03,355 crore 4. Lupin Ltd ₹90,174 crore 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) ₹74,679 crore 6. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ₹62,443 crore 7. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) ₹58,987 crore [All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies) ### Companies close in size in other industries 1. [Coforge Ltd](https://www.sectoralpha.in/stocks/coforge-ltd) ₹90,783 crore · IT - Software 2. [Manipal Health Enterprises Ltd](https://www.sectoralpha.in/stocks/manipal-health-enterprises-ltd) ₹90,610 crore · Hospitals 3. Lupin Ltd ₹90,174 crore 4. [Shree Cement Ltd](https://www.sectoralpha.in/stocks/shree-cement-ltd) ₹89,606 crore · Cement 5. [Federal Bank Ltd](https://www.sectoralpha.in/stocks/federal-bank-ltd) ₹89,124 crore · Banks - Private ## What else do people ask about Lupin? ### What is Lupin's share price today? Lupin Ltd's share price is ₹1,971.90, −2.8% over the past year. The whole company is worth ₹90,188 Cr on the market. In the last 52 weeks it traded between ₹1,929 to ₹2,496; today it is 8% of the way up from the low, 8.7% below its 200-day average (as of 18 November 2026). ### What were Lupin's latest quarterly results? Lupin Ltd reported revenue of ₹7,827 Cr and net profit of ₹1,155 Cr for the Sep 2026 quarter. Revenue rose 11.1% and profit fell 22.2% compared with a year earlier. Earnings per share were ₹25.26. The operating margin was 26.1%, 7.1 percentage points lower than a year earlier (as of 18 November 2026). ### What is Lupin's market cap? Lupin Ltd's market capitalisation is ₹90,188 Cr at a share price of ₹1,971.90. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 18 November 2026). ### How is Lupin performing? Lupin Ltd's share price has been falling for 7 weeks. In its latest quarter, revenue rose 11.1% and profit fell 22.2% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 17 weeks running (as of 18 November 2026). ### Will Lupin's share price go up? This page does not forecast Lupin Ltd's share price. What it shows instead: the share price is ₹1,971.90, and it has been falling for 7 weeks. Its P/E of 17.3× is higher than 4% of its own last 11 years (as of 18 November 2026). ### Who owns Lupin? Promoters own 46.8% of Lupin Ltd, foreign institutions 23.3%, domestic institutions 23.8% and the public 6.1% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.8 percentage points over 8 quarters (as of 18 November 2026). ### Does Lupin have too much debt? No, Lupin Ltd has little debt: its debt is 0.29× its equity, and its operating profit is 19 times its interest bill. FY26 borrowings were ₹6,616 Cr against equity of ₹22,448 Cr. So the returns on this page come from the business, not borrowed money (as of 18 November 2026). ### Where is Lupin in its business cycle? Lupin Ltd's FY26 operating margin was 29.2%, against a 13-year range of 1.3% to 29.2%. The latest quarter was 26.1%, the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 18 November 2026). ### What could break the Lupin story? The main question: yearly earnings per share moved +62.3% while the share price moved −2.8%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 18 November 2026). ### Is Lupin a stock worth studying right now? What the numbers show: Lupin Ltd's P/E is near the low end of its own history, higher than only 4% of past readings, and its quarterly results are still getting worse. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 18 November 2026). ### Is there a Lupin share price forecast for 2026? What management itself guided: FY27 US revenues 1.1-1.2 billion dollars and operating margin 24-25% with H2 moderation flagged. ### Where does this page get Lupin's management information? From Lupin's results calls, its filings and public records on governance, each dated on the page. Management’s plans are shown as plans, never as results. ## Lists - 52 week high & low: https://www.sectoralpha.in/52-week-high-stocks-india - Small & mid cap stocks: https://www.sectoralpha.in/small-cap-stocks-india - Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india This is research, not advice. We’re not SEBI-registered.